Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
GCWB211 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
GCWB211: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EDE-1205 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
EDE-1205: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
GSK-5101956 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
GSK-5101956: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
LT-4008 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
LT-4008: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
![[18F]THK-5105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go](https://synapse-static.patsnap.com/strapi-static/Blog_cover_B_112_156d4a2e9d.jpg)
8 min read
[18F]THK-5105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
[18F]THK-5105: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SIS-302-AA Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
SIS-302-AA: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Recombinant lipase(Groupe Mayoly Spindler) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Recombinant lipase(Groupe Mayoly Spindler): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
VEGFR-1/2 peptide vaccine(Keio University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
VEGFR-1/2 peptide vaccine(Keio University): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NTC011 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
NTC011: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ICS-010 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
ICS-010: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ZKHF-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
ZKHF-001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Psoriasis vaccine(The Immune Response Corporation, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Psoriasis vaccine(The Immune Response Corporation, Inc.): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.